HOOKIPA Pharma Inc. (HOOK)
After hours:
| Previous Close | 0.8590 |
| Open | 0.8400 |
| Bid | 0.7931 x 100 |
| Ask | 0.8295 x 100 |
| Day's Range | 0.8110 - 0.8650 |
| 52 Week Range | 0.4100 - 1.5700 |
| Volume | |
| Avg. Volume | 800,885 |
| Market Cap | 80.249M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4800 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.33 |
Simply Wall St.HOOKIPA Pharma First Quarter 2024 Earnings: Beats Expectations
HOOKIPA Pharma ( NASDAQ:HOOK ) First Quarter 2024 Results Key Financial Results Revenue: US$36.6m (up by US$33.4m from...
GlobeNewswireHOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and Drug Administration (FDA) feedbackHB-200 program received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA)Received FDA clearance for Investigational New Drug (IND) application for HB-700 for the treatment of KRAS mutated cancers NEW YORK and VIENNA, May 09, 2024 (GLOBE N
- GlobeNewswire
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:00 a.m.
